Underestimation of Atypical Ductal Hyperplasia at MRI-guided 9-gauge Vacuum-assisted Breast Biopsy
Overview
Authors
Affiliations
Objective: The purposes of this study were to determine the frequency of diagnosis of atypical ductal hyperplasia (ADH) at MRI-guided 9-gauge vacuum-assisted breast biopsy and to assess the rate of underestimation of ADH at subsequent surgical excision.
Materials And Methods: We conducted a retrospective review of medical records of 237 lesions consecutively detected with MRI and then subjected to MRI-guided 9-gauge vacuum-assisted breast biopsy during a 33-month period. Underestimated ADH was defined as a lesion yielding ADH at vacuum-assisted biopsy and cancer at surgery. Scientific tables were used to calculate 95% CI.
Results: Histologic analysis of MRI-guided vacuum-assisted breast biopsy specimens yielded ADH without cancer in 15 (6%) of 237 lesions. Among 15 patients in whom vacuum-assisted breast biopsy yielded ADH, the median age was 52 years (range, 46-68 years). The median number of specimens obtained was nine (range, 8-18 lesions). Median MRI lesion diameter was 1.3 cm (range, 0.7-7.0 cm). Among 15 MRI lesions, 10 (67%) were nonmasslike enhancement and five (33%) were masses. Surgical excision was performed on 13 lesions. Surgical histologic findings were malignancy in five (38%) of the cases, all ductal carcinoma in situ; high-risk lesion in six (46%) of the cases, including ADH without other high-risk lesions (n = 2), ADH and lobular carcinoma in situ (LCIS) (n = 1), ADH, LCIS, and papilloma (n =1), ADH and papilloma (n = 1), and LCIS (n = 1); and benign in two (15%) of the cases. These data indicated an ADH underestimation rate of 38% (95% CI, 14-68%).
Conclusion: ADH without cancer was encountered in 6% of MRI-guided 9-gauge vacuum-assisted breast biopsies. ADH at MRI-guided vacuum-assisted breast biopsy is an indication for surgical excision because of the high (38%) frequency of underestimation of these lesions.
Ozcan B, Yan J, Xi Y, Baydoun S, Scoggins M, Dogan B Eur J Breast Health. 2023; 19(1):1-27.
PMID: 36605469 PMC: 9806944. DOI: 10.4274/ejbh.galenos.2022.2022-12-1.
High-risk lesions of the breast: concurrent diagnostic tools and management recommendations.
Catanzariti F, Avendano D, Cicero G, Garza-Montemayor M, Sofia C, Venanzi Rullo E Insights Imaging. 2021; 12(1):63.
PMID: 34037876 PMC: 8155169. DOI: 10.1186/s13244-021-01005-6.
Gullo R, Vincenti K, Rossi Saccarelli C, Gibbs P, Fox M, Daimiel I Breast Cancer Res Treat. 2021; 187(2):535-545.
PMID: 33471237 PMC: 8190021. DOI: 10.1007/s10549-020-06074-7.
Yalniz C, Rosenblat J, Spak D, Wei W, Scoggins M, Le-Petross C Eur J Breast Health. 2019; 15(4):229-234.
PMID: 31620681 PMC: 6776134. DOI: 10.5152/ejbh.2019.5002.
Speer M, Huang M, Dogan B, Adrada B, Candelaria R, Hess K Br J Radiol. 2018; 91(1090):20180300.
PMID: 29947265 PMC: 6350470. DOI: 10.1259/bjr.20180300.